Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bellerophon Therapeutics Inc | BLPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.1025 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.1025 | 0.1025 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.076 - 7.2089 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.1025 | USD |
Bellerophon Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.22M | 12.23M | - | 0 | -19.83M | -1.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Bellerophon Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/30/2024 | 08:29 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/26/2024 | 13:31 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of acquisition of beneficial.. |
| 1/26/2024 | 09:46 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 1/22/2024 | 14:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/10/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/03/2024 | 12:49 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 10/27/2023 | 09:50 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 10/16/2023 | 19:51 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/16/2023 | 12:59 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request |
| 10/16/2023 | 12:59 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
| 10/13/2023 | 09:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/13/2023 | 07:45 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLPH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 7.00 | 7.2089 | 0.076 | 0.5834074 | 561,594 | -6.90 | -98.54% |
| 3 Years | 4.16 | 12.58 | 0.076 | 3.12 | 518,376 | -4.06 | -97.54% |
| 5 Years | 0.63 | 29.91 | 0.076 | 4.48 | 411,133 | -0.5275 | -83.73% |
Bellerophon Therapeutics Description
| Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension. |
